ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

https://oncologypro.esmo.org/Meeting-Resour...er-outcomes-and-potential-prognostic-factors

Outcomes for radically treated patients with locally-recurrent rectal cancer (LRRC) are improving and this is likely to be due to better staging, advances in surgical technique and increasing use of peri-operative therapies.

Date: 28 Jun 2017
Presenter: Samuel Ngan
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...and-survival-outcomes-for-a-high-risk-cohort

Based on promising phase II data (Chau et al., J Clin Oncol 2006;24:668-74), our institution offers patients with rectal adenocarcinoma threatening the circumferential resection margins (CRMs) on MR...

Date: 28 Jun 2017
Presenter: Kimberly Bennett
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...anced-rectal-cancer-A-monocentric-experience

Neoadjuvant chemoradiotherapy (CRT) has been proven to increase local control in rectal cancer but the optimal interval between CRT and surgery is still unclear.

Date: 28 Jun 2017
Presenter: Liliana Belgioia
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...A-pragmatic-study-for-accuracy-investigation

Transrectal ultrasound (TRUS) is a cost-effective test for prediction of rectal cancer. However, whether the accuracy of TRUS is correlated with tumor location remains obscured.

Date: 28 Jun 2017
Presenter: Jinning Ye
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...diated-patients-with-recurrent-rectal-cancer

Although management of rectal cancer has improved during the last decades, an important fraction of treated patients present local relapse. Reirradiation may be a retreatment option for these patients,...

Date: 28 Jun 2017
Presenter: Ilir Alimehmeti
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...vance-rectal-cancer-Single-center-experience

Colorectal cancer has a mortality of 13.6 per 100.000 inhabitants in Portugal in 2012 and is above the European average. Treatment of locally advanced rectal cancer with adjuvant chemotherapy (CT) after...

Date: 28 Jun 2017
Presenter: Patricia Gago
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...onated-radiotherapy-surgery-and-chemotherapy

The benefit of neoadjuvant hypofractionated radiotherapy (5x5Gy) in terms of reduction of local recurrences and tumour downstaging have been well stablished with the publication of the Stockholm studies.

Date: 28 Jun 2017
Presenter: Alvaro Seguro Fernandez
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...tic-tumor-regression-in-gastric-cancer-model

GC1118 is an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody with a different binding epitope from other EGFR therapeutic antibodies, showing potent inhibition of high-affinity...

Date: 28 Jun 2017
Presenter: Jae-Chul Lee
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

https://oncologypro.esmo.org/Meeting-Resour...ly-Treated-Metastatic-Colorectal-Cancer-mCRC

Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor in development identified...

Date: 28 Jun 2017
Presenter: A Grothey
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon and Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...ge-A-sub-analysis-of-the-CheckMate-040-study

Patients with hepatocellular carcinoma (HCC) are often diagnosed at an advanced age and a large majority progress on current standard-of-care sorafenib therapy. The clinical benefit of systemic therapies...

Date: 28 Jun 2017
Presenter: Anthony El-Khoueiry
Resources: Abstract
Topics: Gastrointestinal Cancers, Hepatobiliary Cancers, Immunotherapy, Therapy